Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
Interested in receiving a copy of the Contemporary Pediatrics journal every issue?
Want to stay up to date with pediatric news? Subscribe to the Contemporary Pediatrics e-newsletter to receive emailed updates regarding new data, pediatric clinical trials, puzzler cases, FDA news, and much more.
Click here to sign up for the free e-newsletter!
You can also follow us on LinkedIn, X, Facebook, and Blue Sky.
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from the week (Monday, June 23, to Friday, June 27, 2025), and click on each link to read and watch anything you may have missed.
The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) met on June 25 and 26, 2025, for the first time since HHS Secretary Robert F. Kennedy Jr. reorganized the committee. During the 2-day meeting, ACIP voted to recommend clesrovimab (Enflonsia; Merck) for RSV prevention in infants and reaffirmed routine influenza vaccination for the 2025–2026 season.
Click here for full meeting details.
On June 26, 2025, Pfizer announced positive topline results from the phase 3 BASIS trial evaluating marstacimab (Hympavzi) in patients aged 12 years and older with hemophilia A or B with inhibitors.
Marstacimab also showed superiority across all secondary bleeding endpoints and was well tolerated with no thromboembolic events reported. Already FDA-approved for patients without inhibitors, marstacimab is the first anti-TFPI therapy in the U.S. and Europe and is now under consideration for regulatory approval in patients with inhibitors.
Click here for full topline results.
Eli Lilly recently shared 24-week results from the ADmirable study evaluating lebrikizumab-lbkz (EBGLYSS) in patients with moderate-to-severe atopic dermatitis (AD) and skin of color, reinforcing the biologic's efficacy and safety in a historically underrepresented population.
Presented at the 2025 RAD conference, the findings showed that 78% of patients achieved EASI-75, with over 88% of individuals with Fitzpatrick skin types V and VI reaching this outcome. Among week-16 responders, 63% achieved EASI-90 by week 24, and 73% transitioned to monthly maintenance dosing. Improvements in itch and post-inflammatory hyperpigmentation were also observed.
Andrew Alexis, MD, MPH, lead investigator of ADmirable, stated, “Being able to communicate to AD patients with skin of color that treatment with lebrikizumab can not only improve the signs and symptoms of AD, but can also result in improvement in AD-associated post-inflammatory pigment changes is extremely impactful and very relevant to this patient population.”
Click here for the full Q+A discussion with Alexis.
On June 24, 2025, the FDA approved a 200 mg/mL autoinjector formulation of belimumab (Benlysta; GSK) for at-home use in children aged 5 years and older with active lupus nephritis (LN), expanding options for subcutaneous biologic therapy in pediatric patients.
Belimumab, a BLyS-specific monoclonal antibody, was previously approved for intravenous use in pediatric LN. The new autoinjector allows at-home administration by a caregiver or provider, helping reduce the burden of frequent clinic visits. The decision was supported by the established safety profile of belimumab and aims to improve treatment flexibility and access.
Click here for full approval details.
New data from the Transgenerational Effect on Adult Morbidity (TEAM) Study revealed that higher third-trimester maternal glycohemoglobin A1 (HbA1) levels in insulin-dependent diabetic pregnancies are significantly associated with increased adult obesity risk in offspring.
The study tracked 161 individuals born between 1978 and 1995 to mothers with insulin-dependent diabetes mellitus (IDDM), assessing body composition in adulthood via DXA scanning. Researchers found that elevated maternal HbA1 levels in the third trimester correlated with higher BMI, visceral fat, and total body fat decades later, independent of maternal BMI or diabetes severity.
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
June 25th 2025Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.
